The involvement of IL-33 in the development of MS, a CNS inflammatory demyelinating autoimmune disease, has been supported by the increased expression of IL-33 and/or ST2 in the CNS lesions of MS patients (13, 19) and EAE mice (29, 55). This evidence concerns the gene IL33 and myeloid sarcoma.